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Objective: To deﬁne the performance characteristics of the LOCIs method for cardiac troponin I on the
Dimension EXL system.
Designs and methods: Three different levels of commercial control (mean concentrations 0.426, 1.42, and
18.64 mg/L) were used for the imprecision study, quantifying separately within-run and between-run
over 20 days. The limit of blank (LoB) and limit of detection (LoD) were assessed with 20 replicates of a
sample without troponin I. Linearity was assessed by regression analysis. In addition, we studied
inaccuracy, carry-over and limit of quantitation and conducted a method comparison with the Stratus CS
(n¼69). The reference interval was determined in 146 healthy blood donors using non-parametric method.
Results: The within-run imprecision (coefﬁcient of variation [CV], %) obtained at each level was 2.4, 1.4% and
2.2%, while the between-run imprecision (CV,%) was 3.3%, 2.9% and 2.5%. Total imprecision was 4.06%, 3.3%
and 3.4% for each control level. The limit of quantitation which corresponds to the troponin
I concentration at which CV¼10% was 0.05 mg/L. Method comparison with the Stratus CS assay produced
the equation: Dimension EXL¼0.002698þ1.0233n(Stratus CS) with a conﬁdence interval from 0.01562
to 0.00626 for the intercept and (0.979 to 1.0875) for the slope. The 99th percentile obtained for the
reference population was 0.047 mg/L.
Conclusions: The LOCI method for cardiac troponin I on the Dimension EXL meets all guidelines
recommended criteria referring to limit of quantitation, imprecision and shows excellent transferability
with the Stratus CS method.
& 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cardiac troponins I or T are the preferred and recommended biomarkers of coronary acute syndromes [1–3] due to their high
myocardial tissue speciﬁcity and high clinical sensitivity. Detection of a rise and/or fall of the troponin measurements, coupled with
clinical symptoms and/or electrocardiogram is necessary to diagnose acute myocardial infarction [4]. Blood samples for the measurement
of troponin should be drawn for biomarker testing at hospital presentation followed by sampling at 6–9 h, although the new high
sensitivity assays make possible the measurement on admission and 3–6 h later, shortening the turnaround time [2]. An increased cTn
concentration is deﬁned as a value exceeding the 99th percentile of a normal reference population, on condition that precision at this level
is optimal [1]. An acceptable imprecision is described by coefﬁcient of variation (CV) at 99th percentile r10% [5], although few assays
meet this requirement. Assays with CV420% at the 99th percentile should not be used [6]. The 99th percentile decision limit for Tn assays
should be determined in each local laboratory by internal studies using the speciﬁc assay [5].
While antibodies against troponin T are produced by a single manufacturer, there are several manufacturers in the case of troponin I.
In addition the cTnI molecule shows a great complexity due to phosphorylation and other post-translational modiﬁcations. So, cTnI
contains two serine residues that can be phosphorylated in vivo by protein kinase A, which means that 4 forms of the protein can coexist
in the cell (dephosphorylated, 2 monophosphorylated and biphosphorylated). Phosphorylation changes the conformation of troponin
I and modiﬁes its interaction with anti-TnI antibodies [7]. Other post-translational modiﬁcations include oxidation, reduction or partial
digestion by proteases [8]. Monoclonal antibodies speciﬁc to several epitopes of cTnI are able to recognize all known modiﬁcations
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circulating in the blood. The diversity of epitopes and manufacturers makes it easy to understand the lack of standardization of cTnI assays
[9].
The existence of different isoforms of troponin, the different speciﬁcity of the immunoassay antibodies, the lack of standardization of
the cardiac troponin I assays and the importance of accurate measurement of troponin levels [5] make it necessary for each laboratory to
establish the metrological characteristics of their assay and the 99th percentile of their reference population [5,10].
The aim of this study was to assess the analytical performance characteristics of the luminescent oxygen channeling immunoassay
(LOCI™) method for cTnI on the Dimension EXL. In addition we determined the 99th percentile of the upper reference limit in a healthy
population and the 10% coefﬁcient of variation cut-off. Finally we performed a method comparison with the Stratus CS, which is used as a
backup method in our laboratory.
2. Materials and methods
The method evaluated for cTnI measurement was LOCI™. LOCI technology utilizes paired synthetic beads in a homogeneous
immunoassay method. The ﬁrst bead (Chemibead) is coated with an analyte-speciﬁc antibody and contains a chemiluminescent dye.
The second bead (Sensibead) is coated with the protein streptavidin and contains a photosensitive dye. In addition to the beads an analyte-
speciﬁc biotinylated antibody reagent is used. The antigen of interest binds the biotinylated antibody and the antibody bound to the
surface of the Chemibead. The two beads form a complex based on the analyte-speciﬁc antibody binding and the strong afﬁnity of
streptavidin for the biotinylated antibody. When this bead complex is exposed to light at 680 nm, the photosensitive dye bound to the
Sensibead releases singlet oxygen. This singlet oxygen rapidly diffuses to and is absorbed by the Chemibead, causing a chemiluminescent
reaction which is measured by spectrophotometry. The performance characteristics of this method were previously published for the
Dimension Vista analyser [11]. Our study was performed on Dimension EXL analyzer (Siemens Healthcare Diagnostics, Erlangen,
Germany).
2.1. Imprecision
Imprecision was determined according to the Spanish Clinical Chemistry Society (SEQC, Sociedad Española de Química Clínica) guideline
[12]. Brieﬂy, three levels of commercial quality controls (Liquicheck Cardiac Markers Plus, Bio-Rad Laboratories, Hercules, CA, USA) with
different concentrations of cTnI (0.475, 1.57 and 18.8 mg/L) were tested 20 times during a day in the same analytical run for calculating the
within-run imprecision. In addition 20 aliquots per level were frozen for the between-run imprecision determination. One aliquot per
level was thawed and analyzed over twenty days. Within-run and between-run imprecision were expressed as coefﬁcient of variation
(%CV). Total imprecision was calculated as the square root of the sum of the squares of the within- and between-run CVs.
2.2. Linearity
Determination of linearity was carried out as described in the CLSI guideline EP6-A [13]. Two samples, one a serum pool with increased
cTnI (42.16 mg/L) and the other diluent matrix without cTnI (CTNI ADIL, Siemens Healthcare Diagnostics, Erlangen, Germany), were used to
prepare seven intermediate dilutions of each specimen. A triplicate analysis in each mix was performed and the linearity was veriﬁed
using regression analysis.
2.3. Limit of detection
Determination of the limits of blank (LoB) and detection (LoD) was carried out as described in the CLSI guideline EP17-A [14].
In accordance with this guideline, we measured the limit of blank deﬁned as the highest value we expect to see in a series of results in a
sample that contains no analyte, measuring the mean and standard deviation of commercial sample diluent (n¼20). The limit of detection
(LoD) was calculated according to the expression: LoD¼LoBþ1.645 SD, where SD is the standard deviation of samples at the LoD.
2.4. Limit of quantitation
The limit of quantitation was determined for cTnI using ﬁve serum pools with mean values of 0.047, 0.0250, 0.045, 0.0675 and 0.095 mg/L.
Samples were run in duplicate, once each day, for a total of 20 days. An Analysis of Variance (ANOVA) was performed to determinate the
within-laboratory imprecision expressed as %CV. The mean concentration (X) for each of the serum pools was then plotted against the
corresponding %CV (Y). The limit of quantitation at imprecision (CV) of 10% was found by interpolation.
2.5. Carry-over assessment
For carry-over evaluation we followed the CLSI protocol [15], using a pool with high cTnI concentrations (A) (mean concentration of
8.56 mg/L) and other one with concentration close to limit of detection (B) (0.05 mg/L). The high pool was ﬁrst analyzed in duplicate
followed by analysis of the low pool in triplicate, obtaining the sequence: A1, A2, B1, B2, B3, which was repeated 10 times during the same
day. The mean of 10 replicate measurements of the low concentration pool was compared with the results obtained after analyzing the
high pool using the appropriate test. Previously we carried out the Kolmogorov–Smirnov test to assess the normality of distribution.
In addition the Broughton [16] carryover constant was found using the following equation:
Kð%Þ ¼ B1mB3m
A2mB3m
where Aim, Bim are the means of the results obtained for the determinations carried out in the order i (i¼1, 2, 3).
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2.6. Upper reference limit (URL)
The 99th percentile was determined according to the Laboratory Medicine Practice Guidelines of the NACB and IFCC Committee for
Standardization of Markers of Cardiac Damage [5]. Brieﬂy, 146 healthy volunteers were selected from the healthy donors from our local
blood bank. Donors reporting consumption of drugs of abuse, smokers and alcohol drinkers were excluded. The individuals included had
no history of disease and no prescription medications documented. Blood samples were collected into lithium heparin tubes and plasma
samples were obtained by centrifugation at 1700g for ﬁve minutes. The samples were processed on the Dimensions EXL™ on
different days.
2.7. Method comparison
We carried out this comparison as described in the CLSI guideline EP9-A2 [17] using the Stratus CS cTnI assay (Siemens Healthcare
Diagnostics, Erlangen, Germany) as the comparison procedure. We used plasma from 69 patients with cTnI concentrations distributed
over the whole analytical range (0.017–40 mg/L). Seven samples were undetectable with the EXL method (o0.017 mg/L), and 6 of them
gave low values (0.017–0.05 mg/L), 36 had values moderately higher than cut-off (0.05–0.5 mg/L), 9 had high values (0.5–2 mg/L) and 9 had
extremely high values (42 mg/L). Samples were analyzed consecutively on the Dimension EXL and Stratus CS over 10 days. To assess the
correlation between the methods we used the Passing-Bablok regression procedure [18]. In addition we performed a Bland–Altman plot
[19] to assess the agreement between two assays. Med Calc 11.3 Statistical Package (MedCalc Software, Ostend, Belgium) and Excel
2007þAnalyse.it (Analyse-It Software, Leeds, UK) were used for the calculations and graphs.
3. Results
3.1. Imprecision
The results for within-run, between-run and total imprecision at the three levels of cTnI tested are shown in Table 1.
The total imprecision obtained at the low, medium and high levels was 4.06%, 3.3% and 3.4%, respectively, which indicate that the assay
shows acceptable imprecision.
3.2. Linearity
The least-square regression after analysis of the successive dilutions of the samples with high (42.16 mg/L) and low (diluent) values of
cTnI yielded the following regression equation: Y¼0.156þ1.02X, where Y is the theoretical concentration and X the mean concentration
for each dilution. The 95% conﬁdence interval (CI) for the intercept (0.155–1.24) includes zero and the CI for the slope (0.964–1.076)
includes unity.
3.3. Limit of blank and limit of detection
The mean measured concentration after 25 replicate measurements of analyte-free diluent was 0.0056 mg/L. The limit of blank, deﬁned
as the upper limit in a series of results in samples without analyte, [14] was 0.009 mg/L. The limit of detection, according to EP17-A, was
calculated as 0.0122 mg/L.
3.4. Limit of quantitation
The precision proﬁle for cTnI is shown in Fig. 1. The 10% CV cut-off was determined to be 0.050 mg/L
3.5. Upper reference limit (URL)
The 99th percentile for 146 healthy individuals, calculated using a non-parametric method was 0.047 mg/L. Use of the method proposed
by Harris and Boyd [20] permitted us to conclude that there were no signiﬁcant differences between men and women.
Table 1
Imprecision of cTnI LOCI method on the Dimension EXL. SD¼standard deviation, CV¼coefﬁcient of variation.
Pool 1 Pool 2 Pool 3
Within-run Mean (mg/L) 0.4264 1.419 18.639
SD (mg/L) 0.01 0.025 0.419
CV% 2.39 1.64 2.251
Between-run Mean (mg/L) 0.409 1.377 17.969
SD (mg/L) 0.0134 0.04 0.451
CV% 3.277 2.9 2.513
Total imprecision CV% 4.057 3.337 3.373
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3.6. Carry-over assessment
The Gaussian distribution of results for the B1 and B3 series was conﬁrmed by the Kolmogorov–Smirnov test. In consequence a t-test
was applied for mean comparison, and showed no signiﬁcant differences between the two sequences (p¼0.699). Signiﬁcant carry-over
was thus excluded. In addition we calculated the Broughton's constant (k) as described above and found k¼0.039%. The difference of
means carryover (B1–B3) was 0.00325 μg/L.
3.7. Method comparison
Method comparison testing for cTnI included a total of 69 plasma specimens covering the range of 0.017–40.57 mg/L. The non
parametric Passing and Bablok regression yielded the following equation Dimension EXL¼0.0027þ1.023x (Stratus CS) and the Pearson
correlation coefﬁcient was r¼0.997. The conﬁdence intervals for intercept, slope and r are shown in Table 2.
The 95% conﬁdence intervals encompass zero for the intercept and 1 for the slope, so we can conclude that both methods produce
interchangeable results.
The Passing-Bablok regression graph and Bland–Altman plot are shown in Figs. 2 and 3.
4. Discussion
Measurement of cardiac troponin is the cornerstone of diagnosis of acute coronary syndrome, which make essential to assess the
fundamental characteristics of the assays used – total imprecision, 99th percentile of the reference population and functional sensitivity.
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Fig. 1. Limit of quantitation (precision proﬁle) of cTnI on the Dimension EXL. Testing was performed in duplicate over 20 non-consecutive test days. The coefﬁcient of
variation (CV,%) for each of the serum pools was then plotted against the mean cTnI concentration.
Table 2
Results of Passing-Bablok regression for the comparison between the Dimension EXL (y) and the
Stratus CS cTnI (x) methods. The 95% conﬁdence intervals are shown in parentheses.
Regression equation y¼0.0027þ1.023x
Intercept (95% CI) 0.0027 (0.01562 to 0.00626)
Slope (95% CI) 1.023 (0.979–1.0875)
r (95% CI) 0.997 (0.9948–0.9980)
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Fig. 2. Passing-Bablok linear regression for the comparison between Dimension EXL and Stratus CS cTnI methods.
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In addition, lack of harmonization between different assays for cTnI requires comparisons between different methods, especially when
they are used in the same institution [9].
We found that the analytical performance characteristics of LOCI™ method for cTnI on the Dimension EXL are acceptable. The
imprecision is similar to the manufacturer's claims and the method is linear across a wide analytical range (0.017–40 mg/L). The limit of
detection calculated according to the EP-17-A guideline [14] was 0.012 mg/L.
The 99th percentile in our reference population was 0.047 mg/L, lower than the cut-off claimed by the manufacturer, which highlights
the need to determine cut-offs for each population [3,5]. The limit of quantiﬁcation or functional sensitivity was 0.05 mg/L. The limit of
quantitation is of particular signiﬁcance in the diagnosis of acute coronary syndrome. We obtained the same limit of quantiﬁcation as
declared by the manufacturer.
Sample carryover was not statistically signiﬁcant according to t-test (p¼0.699). The Broughton's constant (k) indicates that there is no
signiﬁcant contamination between samples, given that values less than 1% are permitted [16]. In addition we can conclude that there is no
clinically signiﬁcant carryover, because the difference of mean values between the samples most and least affected (B1–B3) was
0.00325 ug/L, which is less than the imprecision at low concentrations.
A method comparison with cTnI measurement on the Stratus CS was essential for us because this method is our laboratory's alternative
method. The correlation was adequate (r¼0.997), without proportional or constant errors as indicated by the conﬁdence intervals for the
intercept and slope.
Previous studies of Arrebola et al. [11] and Kelley et al. [21] have assessed the analytical performance for LOCI cardiac troponin I on the
Dimension Vista™, but we have not found studies published for the LOCI method on the Dimension EXL™.
In conclusion the LOCI method for cardiac troponin I on the Dimension EXL meets all guidelines and recommended criteria for limit of
quantitation and imprecision, and the transferability with the Stratus CS method is excellent.
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